Bone Mineral Density As an Individual Prognostic Biomarker in NSCLC Patients Treated with Immune Checkpoint Inhibitors

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 May 3

PMID 38698843

Authors

Jie Lou

Bingxin Gong

Yi Li

Yusheng Guo

Lin Li

Jing Wang

Weiwei Liu

Ziang You

Hongyong Zhang

Feng Pan

Bo Liang

Lian Yang

Guofeng Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Immune checkpoint inhibitors (ICIs) have left a deep impression in the treatment of non-small cell lung cancer (NSCLC), however, not all patients benefit from it. The purpose of this study was to investigate the prognostic value of baseline bone mineral density (BMD) derived from chest computed tomography (CT) scans in NSCLC patients treated with ICIs.

Methods: This study included patients with advanced NSCLC who underwent ICI treatment at the Wuhan Union Hospital from March 2020 to October 2022. Baseline BMD was evaluated at non-contrast chest CT at the level of first lumbar vertebra. Patients were divided into BMD-lower group and BMD-higher group according to the optimal cutoff value calculated by X-tile software. Baseline characteristics of the two groups were compared and variables between the two groups were balanced by propensity score matching (PSM) analysis. We calculated the objective response rate (ORR) and disease control rate (DCR) of the two groups and analyzed overall survival (OS) and progression-free survival (PFS) using BMD and other clinical indexes through Cox regression models and Kaplan-Meier survival curves.

Results: A total of 479 patients were included in this study, and all patients were divided into BMD-lower group (n=270) and BMD-higher group (n=209). After PSM analysis, each group consisted of 150 patients. ORR (43.3% vs. 43.5% before PSM, = 0.964; 44.7% vs. 44.7% after PSM, = 1.000) and DCR (91.1% vs. 94.3% before PSM, = 0.195; 93.3% vs. 96.7% after PSM, =0.190) were similar in two groups. There was no statistically significant relationship between BMD degree and PFS before (16.0 months vs. 18.0 months, = 0.067) and after PSM analysis (17.0 months vs. 19.0 months, = 0.095). However, lower BMD was associated with shorter OS both before (20.5 months vs. 23.0 months, < 0.001) and after PSM analysis (20.0 months vs. 23.0 months, = 0.008).

Conclusion: Lower baseline BMD is associated with worse clinical outcomes in NSCLC patients treated with ICIs. As a reliable and easily obtained individual prognostic biomarker, BMD can become a routine detection indicator before immunotherapy.

References

Himelstein A, Foster J, Khatcheressian J, Roberts J, Seisler D, Novotny P . Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2016; 317(1):48-58. PMC: 5321662. DOI: 10.1001/jama.2016.19425. View

Sharma P, Parikh N, Yu J, Barman P, Derstine B, Sonnenday C . Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients. Liver Transpl. 2016; 22(8):1092-8. PMC: 4961525. DOI: 10.1002/lt.24458. View

Takenaka Y, Oya R, Takemoto N, Inohara H . Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle. 2021; 12(5):1122-1135. PMC: 8517360. DOI: 10.1002/jcsm.12755. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Moseley K, Naidoo J, Bingham C, Carducci M, Forde P, Gibney G . Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer. 2018; 6(1):104. PMC: 6180387. DOI: 10.1186/s40425-018-0417-8. View

de Castro J, Garcia R, Garrido P, Isla D, Massuti B, Blanca B . Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications. Clin Lung Cancer. 2015; 16(6):431-46. DOI: 10.1016/j.cllc.2015.06.004. View

Reck M, Remon J, Hellmann M . First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):586-597. DOI: 10.1200/JCO.21.01497. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Lee S, Chung C, Oh S, Park S . Correlation between Bone Mineral Density Measured by Dual-Energy X-Ray Absorptiometry and Hounsfield Units Measured by Diagnostic CT in Lumbar Spine. J Korean Neurosurg Soc. 2014; 54(5):384-9. PMC: 3873350. DOI: 10.3340/jkns.2013.54.5.384. View

10.

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

11.

Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N . Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival. J Clin Oncol. 2023; 41(15):2706-2712. PMC: 10414695. DOI: 10.1200/JCO.23.00225. View

12.

Berent T, Dorschner J, Craig T, Drake M, Westendorf J, Kumar R . Lung tumor cells inhibit bone mineralization and osteoblast activity. Biochem Biophys Res Commun. 2019; 519(3):566-571. PMC: 6879054. DOI: 10.1016/j.bbrc.2019.09.045. View

13.

Ilic I, Potthoff A, Borger V, Heimann M, Paech D, Anton Giordano F . Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC). Cancers (Basel). 2022; 14(19). PMC: 9562667. DOI: 10.3390/cancers14194633. View

14.

Jones D, Nakashima T, Sanchez O, Kozieradzki I, Komarova S, Sarosi I . Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006; 440(7084):692-6. DOI: 10.1038/nature04524. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Toshima T, Yoshizumi T, Ikegami T, Harada N, Itoh S, Mano Y . Impact of Osteopenia in Liver Cirrhosis: Special Reference to Standard Bone Mineral Density with Age. Anticancer Res. 2018; 38(11):6465-6471. DOI: 10.21873/anticanres.13009. View

17.

Passaro A, Brahmer J, Antonia S, Mok T, Peters S . Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022; 40(6):598-610. DOI: 10.1200/JCO.21.01845. View

18.

van Dam P, Verhoeven Y, Trinh X, Wouters A, Lardon F, Prenen H . RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2019; 133:85-91. DOI: 10.1016/j.critrevonc.2018.10.011. View

19.

Tamura T, Shomori K, Nakabayashi M, Fujii N, Ryoke K, Ito H . Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. Oncol Rep. 2011; 25(4):1139-43. DOI: 10.3892/or.2011.1152. View

20.

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-22. PMC: 3090685. DOI: 10.1016/S0140-6736(10)62344-6. View